GALECTIN THERAPEUTICS INC GALT
We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in metabolic
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M | $18.0M | $7.5M | $6.5M | $11.7M | $15.3M |
| SG&A | $5.8M | $5.9M | $5.9M | $6.6M | $6.4M | $5.5M | $6.0M | $7.1M | $4.5M | $6.2M |
| Total operating expenses | $20.1M | $42.4M | $38.1M | $38.4M | $30.2M | $23.4M | $13.4M | $13.6M | $16.2M | $21.5M |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M | -$23.4M | -$13.4M | -$13.6M | -$16.2M | -$21.5M |
| Interest expense | $7.3M | $5.5M | $2.8M | $1.0M | $489.0K | $87.0K | $87.0K | $336.0K | $12.0K | — |
| Pre-tax income | -$30.8M | -$47.0M | — | — | — | — | — | — | — | — |
| Income tax | $0 | $0 | — | — | — | — | — | — | — | — |
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M | -$30.5M | -$23.5M | -$13.3M | -$13.9M | -$16.2M | -$21.4M |
| EPS, basic | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | — | — | — | — |
| EPS, diluted | -0.48 | -0.76 | -0.74 | -0.65 | -0.52 | -0.41 | -0.39 | -0.38 | -0.49 | -0.76 |
| Shares, diluted (wtd. avg.) | 63.9M | 62.3M | 60.2M | 59.4M | 58.5M | 57.0M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M | $27.1M | $47.5M | $8.3M | $3.1M | $15.4M |
| Total current assets | $19.4M | $17.3M | $27.7M | $20.6M | $41.8M | $29.5M | $48.2M | $8.8M | $3.8M | $15.8M |
| Property, plant and equipment | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other intangibles | — | — | — | — | — | — | — | $0 | $0 | $1.0K |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M | $29.6M | $48.5M | $9.0M | $4.2M | $15.8M |
| Accounts payable | $3.2M | $5.7M | $6.4M | $3.9M | $1.8M | $1.3M | $1.7M | $297.0K | $608.0K | $910.0K |
| Total current liabilities | $8.0M | $35.4M | $15.7M | $13.0M | $9.0M | $5.4M | $2.8M | $2.1M | $3.0M | $3.8M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M | $5.4M | $2.9M | $2.1M | $3.0M | $3.8M |
| Retained earnings | -$432.5M | -$401.6M | -$354.4M | -$309.6M | -$270.7M | -$240.0M | -$216.4M | -$196.2M | -$181.2M | -$163.7M |
| Total equity | -$127.9M | -$104.8M | -$62.0M | -$33.9M | $893.0K | $22.5M | $43.9M | $5.2M | -$530.0K | $10.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M | -$20.6M | -$10.8M | -$10.2M | -$15.9M | -$16.4M |
| Depreciation and amortisation | — | — | — | — | — | — | — | $0 | $1.0K | $7.0K |
| Stock-based compensation | $1.7M | $2.4M | $2.3M | $2.9M | $2.1M | $1.8M | $1.7M | $4.4M | $1.1M | $2.5M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 |
| Financing cash flow | $26.5M | $31.2M | $40.0M | $10.0M | $36.8M | $263.0K | $50.1M | $15.4M | $3.6M | $5.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-012155.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$21.4M | -$16.2M | -$13.9M | -$13.3M | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |